Christine Jenkins

Sep 15, 2024 | insightplus.mja.com.au | Christine Jenkins

Evidence-based communication approaches to raise awareness, promote preventive behaviours and attitudes toward respiratory wellbeing are needed to turn negative messages about lung disease into lung health for all. Of the leading causes of death in this country, lung disease is the second biggest, following closely behind heart disease. Yet lung disease slips under people’s radars and is disproportionately under-funded across a range of its key conditions.

Jul 25, 2024 | erj.ersjournals.com | Joan B. Soriano |Sara Lumbreras |Christine Jenkins

Conflict of interest: J.B. Soriano reports grants from Chiesi, GSK, Linde and Novartis via Hospital Universitario de La Princesa, and from 2020 to 2024 participated in speaking activities, advisory committees and consultancies for Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, CNPT, ERS, FTH, Gebro, Grifols, GSK, IHME, Laminar Pharma, Linde, Lipopharma, Menarini, Mundipharma, Novartis, OMS/WHO, Pfizer, ResApp, RiRL, ROVI, SEPAR, Seqirus, WHO EUR, Takeda and Zambon;...

Jun 18, 2024 | thorax.bmj.com | Christine Jenkins

Integrated disease management: good news but more work to do Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Oct 24, 2023 | emjreviews.com | John R. Hurst |Helen Reddel |Christine Jenkins |Ekaterina Maslova

Introduction John Hurst Hurst set the scene by highlighting that policymakers face significant challenges in addressing the post-COVID-19 priorities of resolving health inequity, building system resilience, and reducing greenhouse gas (GHG) emissions.1 Improvements in respiratory care have stalled in recent years.2 He noted that this slow-down has not occurred universally amongst all patients living with respiratory disease; rather, a disproportionate burden of mortality and morbidity due to...

Sep 10, 2023 | erj.ersjournals.com | Joan B. Soriano |Christine Jenkins

FootnotesConflict of interest: C. Jenkins reports grants from GlaxoSmithKline, lecture honoraria from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis and Chiesi, travel support from GlaxoSmithKline, AstraZeneca and Novartis, data safety monitoring board participation with AstraZeneca, and leadership roles with Lung Foundation Australia and the Asbestos and Dust Diseases Research Institute, outside the submitted work. J.B. Soriano has nothing to disclose. Received June 8, 2023.